Hepatitis vaccination til patienter med HIV infektion. Betydning af adjuverende interleukin-2
Phase 1
- Conditions
- Patienter med Hiv infektion har øget risiko for hepatitis A og hepatitis B. Sundhedsmyndigheder anbefaler vaccination. Effekt er imidlertid mindre end for raske personer. Forsøget tester om adjuverende interleukin-2 øger effekt.
- Registration Number
- EUCTR2005-002171-33-DK
- Lead Sponsor
- Aalborg Sygehus Syd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
HIV infektion
Alder > 18 år
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Serologisk dokumentation af tidligere infektion med hepatitis A eller hepatitis B
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Effekt af hepatit vaccination hos hiv patienter;Secondary Objective: ;Primary end point(s): Antistof respons efter 3 injektioner Twinrix
- Secondary Outcome Measures
Name Time Method